Chargement en cours...
Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines
MET targeted therapies are under clinical evaluation for non‐small‐cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors (TKI) against MET have varying degrees of specificity. Tivantinib (ARQ 197) is reported to be a non‐ATP competitive selective MET inhibitor. We aimed to compare the activi...
Enregistré dans:
| Publié dans: | Mol Oncol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528687/ https://ncbi.nlm.nih.gov/pubmed/25226813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.08.011 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|